Comprehensive Comparison Between Adjuvant Targeted Therapy and Chemotherapy for EGFR-Mutant NSCLC Patients: A Cost-Effectiveness Analysis

BACKGROUND: Chemotherapy has been the current standard adjuvant treatment for early-stage non-small-cell lung cancer (NSCLC) patients, while recent studies showed benefits of epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI). We conducted a cost-effectiveness analysis to comprehe...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Wenqian, Guo, Hanfei, Li, Lingyu, Cui, Jiuwei
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027108/
https://www.ncbi.nlm.nih.gov/pubmed/33842322
http://dx.doi.org/10.3389/fonc.2021.619376

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8027108/
https://www.ncbi.nlm.nih.gov/pubmed/33842322
http://dx.doi.org/10.3389/fonc.2021.619376

Ejemplares similares